Abstract
The advent of hybridoma/monoclonal antibody technology in 1975 (1) and gene, cloning procedures have drastically influenced both the understanding and practice of pathology. Using these methodologies and reagents, applications have been developed in the research laboratory, distributed to the clinical setting, and now often impact on the diagnosis and management of human disease. It is the authors’ intent to focus this chapter on some recently developed monoclonal antibody applications in human pathology using immunohistochemical techniques. The text will be roughly divided into three parts: background information and general principles, practical applications, and monoclonal antibodies as probes to investigate tumor biology and oncogene expression.
Keywords
- Malignant Mesothelioma
- Fine Needle Aspiration Biopsy
- Tumor Associate Antigen
- Laminin Receptor
- Serous Effusion
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kohler M, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495, 1975.
Sell S: Cancer Markers, Diagnostic and Developmental Significance. Clifton, NJ, Human Press, 1980.
Stefarti M: Enzymes, isoenzymes, and enzyme variants in the diagnosis of cancer. Cancer 55: 1391, 1985.
Van Lente F, Shamberger RJ: Defining a role for enzymes in cancer diagnosis. Diag Med 47, June 1983.
Wu JT: Applications of enzymes: tumor markers, new enzymes, and atypical isoenzymes. J Med Technol 7: 438, 1985.
Mirecki DM, Jordan VC: Steroid hormone receptors and breast cancer. Lab Med 16: 287, 1985.
Hakomori S: Tumor-associated carbohydrate antigens. Ann Rev Immunol 2: 103, 1984.
Ohosh BC (ed): Tumor Associated and Other Related Markers: McGraw Hill Publishers (in press).
Colcher D, Horan Hand P, Nuti M et al.: A spectrum of monoclonal antibodies reactive with mammary tumor cells. Proc Natl Acad Sci USA 78: 3199, 1981.
Nuti M, Teramoto YA, Mariani-Costantini R et al.: A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 29: 539, 1982.
Stragmignoni D, Bowen R, Atkinson B et al.: Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 31: 543, 1983.
Horan Hand P, Colcher D, Salomon D, Ridge J, Noguchi P, Schlom J: Influence of spatial configuration of carcinoma cell populations on the expression of fa tumor-associated glycoprotein. Cancer Res, 45: 833–840, 1985.
Johnson VG, Schlom J, Paterson AJ et al.: Analysis of a human tumor- associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res, 46: 850, 1986.
Friedman E, Thor A, Horan Hand P, Schlom J: Surface expression of tumor-associated antigens in primary cultured human colonic epithelial cells from carcinomas, benign tumors and normal tissues. Cancer Res, 45: 5648, 1985.
Greiner J, Horan Hand P, Pestka S, Noguchi P, Fisher P, Colcher D, Schlom J: Selection and enhancement (by recombinant interferon) of carcinoma cell surface antigens using monoclonal antibodies. In: Cancer Cells 1: The Transformed Phenotype, pp. 285–292, Cold Spring Harbor Lab., 1984.
Colcher D, Zalutsky M, Kaplan W et al.: Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res, 43: 736–742, 1983.
Schlom J, Greiner J, Horan Hand P, Colcher D, Inghirami G, Weeks M, Pestka S, Fisher PB, Noguchi P, Kufe D: Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer. Cancer 54: 2777–2794, 1984.
Keenan AM, Colcher D, Larson SM, Schlom J: Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3. J Nucl Med 25: 1197–1203.
Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J: The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res (in press).
Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J: Monoclonal antibody B72.3 defines tumor associated antigen (TAG-72) in ovarian carcinoma. JNCI (in press).
Colcher D, Carrasquillo JA, Sugarbaker P, Bryant G, Esteban J, Simpson D, Thor A, Reynolds JR, Horowitz M, Larson SM, Schlom J: Biodistribution of monoclonal antibody B72.3 (I-131) in colon cancer patients. Proc of Society of Nuclear Medicine. P15, 1985.
Paterson AJ, Schlom J, Sears NF, Bennett J, Colcher D: A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG- 72) using monoclonal antibody B72.3 Cancer Res (in press).
Johnston WW: The malignant pleural effusion: a review of cytopathological diagnoses on 584 specimens from 472 consecutive patients. Cancer 56: 905, 1984.
Kufe D, Inghirami G, Abe M et al.: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma, 3: 223, 1984.
Sekine H, Ohno T, Kufe DW: Purification and characterization of high molecular weight glycoprotein detectable in human milk and breast carcinoma. J Immunol, 135, 1985.
Lundy J, Thor A, Maenza R et al.: Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. Br Cancer Res and Treat, 5: 269, 1985.
Szpak CA, Johnston WW, Lottich SC, Kufe D, Thor A, Schlom J: Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. Acta Cytol, 28: 356, 1984.
Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J: Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Res, 45: 1894–1900, 1985.
Martin SE, Moshiri S, Thor A, Vilasi V, Chu EW, Schlom J: Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. Am J Clin Path (in press).
Johnst on WW, Szpak CA, Thor A, Schlom J: The use of monoclonal antibody (B72.3) as a novel immunocytochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsies. Human Path (in press).
Lundy J, Lozowski M, Mishriki Y: Monoclonal antibody B72.3 as a diagnostic adjunct in fine needle aspirates of breast masses. Ann Surg (in press).
Nuti M, Mottolese M, Viora M, Donnorso RP, Schlom J, Natali PG: Use of monoclonal antibodies to human breast tumor associated antigens in fine needle aspirate cytology. Int J Cancer (in press).
Szpak CA, Johnston WW, Roggli V et al.: The diagnostic distinction between malignaht mesothelioma of the pleura and adenocarcinoma of the lung defined by a monoclonal antibody (B72.3). Am J Path (in press).
Antman KH, Blum EH, Greenberger JS et al.: Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med, 68: 356, 1980.
Legha SS, Muggia, FM: Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med, 87: 613, 1977.
Wang N, Huang SN, Gold P: Absence of carinoembryonic antigen-like material in mesothelioma. An immunohistochemical differentiation from other lung cancer. Cancer, 44: 937, 1979.
Corson JM, Pinkus GS: Mesothelioma: Profile of keratin proteins and carcinoembryonic antigen. An immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol, 108: 80, 1982.
Said JW, Nash G, Tepper G et al.: Keratin proteins and carcinoembryonic antigen in lung carcinoma: An immunoperoxidase study of 54 cases, with ultrastructural correlations. Hum Pathol, 14: 70–76, 1983.
Holden J, Churg A: Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol, 8: 277, 1984.
Liotta LA: Tumor invasion and metastases: role of the basement membrane. Am J Path, 117: 340, 1984.
Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest, 49: 636, 1983.
Barsky SH, Rao CN, Hyams D, Liotta LA: Characterization of a laminin receptor from human breast carcinoma tissue. Breast Cancer Res Treat, 4: 181, 1984.
Barsky SH, Rao CN, Williams JE, Liotta LA: Laminin molecular domains which alter metastasis in a murine mode. J Clin Invest, 74: 0001, 1984.
Liotta LA, Horan Hand P, Rao CN, Bryant G, Barsky SH, Schlom J: Monoclonal ntibodies to the human laminin receptor recognize structurally distinct sites. Expt Cell Res, 156: 117, 1985.
Horan Hand P, Thor A, Schlom J, Rao CN, Liotta LA: Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. Cancer Res, 45: 2713, 1985.
Land H, Parada L, Weinberg RA: Cellular oncogenes and multistep carcinogenesis. Science, 222: 771, 1983.
Shih TY, Weeks MO: Oncogenes and cancer: the p21 ras genes. Cancer Invest, 2: 109, 1984.
Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M: Oncogenes in solid human tumours. Nature (London), 300:, 539–542, 1982.
Kraus MH, Yuasa Y, Aaronson SA: A position 12-activated H-ras oncogene in all HS578T mammary carcinoma cells but not normal mammary cells of the same patient. Proc Natl Acad Sci USA, 81: 5384, 1984.
Fujita J, Srivastava SK, Kraus MH, Rhim JS, Tronick SR, Aaronson SA: Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc Natl Acad Sci USA, 82: 3849, 1985.
Horan Hand P, Thor A, Wunderlich D et al.: Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci, 81: 5227, 1984.
Thor A, Horan Hand P, Wunderlich D et al.: Monoclonal antibodies define differential ras gene expression in malignant and benign colonic disease states. Nature, 311: 562, 1984.
McCormick F, Clark BFC, La Cour TF, Kjeldgaard M, Norskov-Lauritsen L, Nyborg J: A model for ther tertiary structure of p21, the product of the ras oncogene. Science, 230: 78, 1985.
Viola MV, Tromowitz F, Oravez S, Deb S, Schlom J: ras oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Expt Med, 161: 1213, 1985.
Feinberg A, Vogelstein B, Droller M, Baylin S, Nelkin, B: Mutations affecting the 12th amino acid of c-Ha-ras oncogene product occur infrequently in bladder cancer. Science, 220: 1175.
Fujita J, Yoshida O, Yuasa Y, Rhim J, Hatanaka M, Aaronson S: Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature, 309: 464, 1984.
Viola MJ, Tromowitz F, Oravez S, Deb S, Sinkel G, Lundy J, Horan Hand P, Thor A, Schlom J: Expression of ras oncogene p21 in prostate cancer. NEJM 314: 133, 1986.
Spandidos DA, Kerr IB: Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum. Br J Cancer 49: 681, 1984.
Spandidos DA, Agnantis NJ: Human malignant tumors of the breast, as compared to their respective normal tissue have elevated expression of the Harvey ras oncogene. Anticancer Res, 4: 269, 1984.
DeBortoli ME, Abou-Issa H, Haley BE, Cho-Chung YS: Amplified expression of P21 ras protein in hormone-dependent mammary carcinoma of humans and rodents. Biophys Res Commun, 127: 699, 1985.
Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gutterman JU: Expression of p21 ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci USA, 82: 1795, 1985.
Horan Hand P, Thor A, Caruso A, Wunderlich D, Muraro R, Weeks MO, Vilasi V, Schlom J: Comparisons of qualitative and quantitative immunoassays for ras p21. In: Monoclonal Antibodies and Cancer Therapy p 23–36, Alan R. Liss, Inc., 1985.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
Thor, A. et al. (1987). Tumor Associated Antigens and Oncogene Products Defined by Monoclonal Antibodies. In: Ruiter, D.J., Fleuren, G.J., Warnaar, S.O. (eds) Application of Monoclonal Antibodies in Tumor Pathology. Developments in Oncology, vol 50. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3299-9_16
Download citation
DOI: https://doi.org/10.1007/978-94-009-3299-9_16
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7981-5
Online ISBN: 978-94-009-3299-9
eBook Packages: Springer Book Archive